Trial Profile
A Double-blind, Randomized, Placebo-controlled, Multicenter Dose-ranging Study To Evaluate The Efficacy And Safety Of Pf-04236921 In Subjects With Systemic Lupus Erythematosus (Sle)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Dec 2022
Price :
$35
*
At a glance
- Drugs TOUR-006 (Primary)
- Indications Systemic lupus erythematosus
- Focus Therapeutic Use
- Acronyms BUTTERFLY
- Sponsors Pfizer
- 02 Dec 2022 According to a Stoke Therapeutics media release, twelve-month analysis from the trial was presented at the American Epilepsy Society (AES) 2022 Annual Meeting.
- 02 Dec 2022 Results published in a Stoke Therapeutics media release.
- 29 Nov 2022 According to a Stoke Therapeutics media release, twelve-month analysis from the trial will be presented at the American Epilepsy Society (AES) 2022 Annual Meeting.